Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

Microb-AI-ome Federated artificial intelligence for privacy-preserving international stratification of colorectal cancer patients

Coordinator
University of Hamburg, Germany
Runs
1 April 2023 to 31 March 2028
Status
Running
EU funding
€6.0m
Total cost
€6.0m
Partners
8 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101079777

What the project is doing

In the project's own words, from its summary on CORDIS.

In the EU, 1 in 35 women and 1 in 23 men will be diagnosed with colorectal cancer (CRC) in their life span (ca. 340,000 cases and 156,000 deaths in 2020) causing an annual economic burden of ca. 20 billion EUR. Identifying CRC early enables better treatment options. Screening usually entails a quantitative faecal immunological test (FIT) to predict the need of colonoscopy for the detection of colorectal lesions, an expensive and invasive procedure.

We aim to predict this need with specificity increased by >20 percentage points by using metagenomic microbiomes. We hypothesise that computational microbiome profiles extracted using artificial intelligence (Al) technology will allow for optimised personal therapy stratification. However, clinicians do not have access to broad microbiome data. With Microb-AI-ome, we will develop a novel kind of computational stratification technology to enable microbiome-enhanced precision medicine of CRC.

Metagenomic microbiome data to date is distributed over many national registries, and privacy regulations are hindering its effective integration. With Microb-AI-ome, we will overcome this barrier by establishing the first privacy-preserving federated big data network in CRC research. We will integrate isolated, national databases into one international federated database network - rather than a cloud - covering metagenomes for over 5,000 individuals screened for CRC, and an expected total of 100,000 by 2026.

Microb-AI-ome ensures that no sensitive patient data will leave the safe harbours of the local databases while still allowing for the classification of clinical CRC phenotypes, which we will demonstrate in clinical practice allowing regulatory bodies to adopt evidence-based guidelines. Our consortium combines expertise in CRC and its treatment, microbiomics, artificial intelligence, software development, and privacy protection to close the gap between privacy and big data in international medical research.

Topics

Who is involved

OrganisationCityCountryRole
University of HamburgHamburgGermanyCoordinator
Research Institute AG & Co KgWienAustriaParticipant
Tp21 GmbHBerlinGermanyParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnementParisFranceParticipant
Mater Misericordiae University HospitalDublinIrelandParticipant
University College Cork - National University of Ireland, CorkCorkIrelandParticipant
Egnosis SRLSfantu GheorgheRomaniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI